Biotech Calendar: Key Dates for February

February's list of important, potentially stock-moving biotech events.
By Adam Feuerstein ,

BOSTON (TheStreet) -- A calendar of important, potentially stock-moving biotech events for February:

Feb. 2

Ironwood Pharmaceuticals

(IRWD) - Get Report

initial public offering.

Feb 8 - 9

BIO CEO Conference, New York.

Feb. 9

FDA approval decision date for

GlaxoSmithKline

(GSK) - Get Report

and

Xenoport's

(XNPT)

Solzira for restless leg syndrome.

Feb. 10

FDA Oncologic Drug Advisory Committee meeting to discuss

Cell Therapeutics'

(CTIC) - Get Report

lymphoma drug pixantrone. FDA's briefing documents for this meeting likely available Feb. 8 - 9.

Micromet

( MITI) investor/analyst day.

Feb. 11

FDA approval decision date for

Labopharm's

( DDSS) trazadone contramid for major depressive disorder.

Feb. 12

FDA approval decision date for

Cadence Pharmaceuticals'

(CADX)

Acetevance (intravenous acetaminophan) for hospital use.

Feb. 13

FDA approval decision date for

Gilead Sciences'

(GILD) - Get Report

Cayston antibiotic for cystic fibrosis.

Feb. 16-19

Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco

Gilead will be presenting phase II data on its "Quad pill" for HIV.

Feb. 23

FDA advisory panel to review

Salix Pharmaceuticals'

(SLXP)

Xifaxan in hepatic encephalopathy.

Feb 25

ImmunoGen

(IMGN) - Get Report

investor/analyst meeting.

Feb. 28

FDA approval decision date for

Shire's

( SHPGY) velaglucerase in Gaucher's disease.

Ongoing FDA reviews with no firm decision date:

Auxillium Pharmaceuticals

(AUXL)

and

Pfizer's

(PFE) - Get Report

Xiaflex for Dupuytren's Contracture.

Mannkind's

(MNKD) - Get Report

Afresa (inhaled insulin) for diabetes.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on

Twitter

.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.

Loading ...